

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2005/000280

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. 7: A61K 39/395, G01N 33/532

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WPIDS, MEDLINE, CAPLUS, BIOSIS, BIOTECHABS (surface, membrane, lambda light chain, Bence Jones, myeloma, lymphoid, antibod, binding)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Abe, M., et al; American Journal of Clinical pathology, (1993); 100 (1): 67-74.	1-27
Y	"Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies." (Whole document)	
X	Boux, H. A., et al; Journal of Experimental Medicine, (1983); 158 (5): 1769-1774.	1-3, 8, 9,13,
Y	"A tumor-associated antigen specific for human kappa myeloma cells." (Whole document)	18-20 and 25-27
X	Walker, K. Z., et al; European Journal of Nuclear Medicine, (1986); 12 (9): 461-467.	1-3, 8, 9,13,
Y	"A rat model system for radioimmunodetection of kappa myeloma antigen on malignant B cells." (Whole document)	18-20 and 25-27

 Further documents are listed in the continuation of Box C See patent family annex

* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
24 March 2005Date of mailing of the international search report
07 APR 2005Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaaustralia.gov.au
Facsimile No. (02) 6285 3929Authorized officer
ANITA PREMKUMAR
Telephone No : (02) 6283 2515

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2005/000280

(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Lauder. I., et al; Journal of Pathology, (1985); 145 (3): 259-268. "Surface membrane phenotypic expression and treatment response of malignant lymphomas." (Abstract; Introduction; Page 260, col 2, para 2)	25 and 27
X	Arpin. C., et al; Journal of Experimental Medicine, (1998); 187 (8): 1169-1178. "The normal counterpart of IgD myeloma cells in germinal center displays extensive mutated IgVH gene, C μ -C δ switch, and λ light chain expression." (Abstract; Introduction; Page 1172, col 2, para 2)	25 and 27
X	Bradwell. A. R., et al; Clinical Chemistry, (2001); 47 (4): 673-680. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine" (Whole document)	18-20 and 25-27
X	Tillyer. C. R., et al; Journal of Clinical Pathology, (1991); 44 (6): 466-471. "Immunoturbidimetric assay for estimating free light chains of immunoglobulins in urine and serum." (Whole document)	18-20 and 25-27
X	Bergsagel. P. L., et al; Blood (1995); 85 (2): 436-447. "In multiple myeloma, clonotypic B lymphocytes are detectable among CD19 $^{+}$ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chains." (Page 437, col 2, para 3)	25 and 27
Y	Bodey. B., et al; Current Pharmaceutical Design, (2000); 6 (3): 261-276. "Genetically engineered monoclonal antibodies for direct antineoplastic treatment and cancer cell specific delivery of chemotherapeutic agents." (Abstract)	1-27
Y	Tordsson. J. M., et al; Cancer Immunology Immunotherapy, (2000); 48 (12): 691-702. "Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma." (Abstract)	1-27
Y	Kovar. M., et al; Journal of Controlled Release, (2003); 92 (3): 315-330. "HPMA copolymer-bound doxorubicin targeted to tumor specific antigen of BCL1 mouse B cell leukemia." (Abstract)	1-27